{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:10:07Z","timestamp":1784049007197,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    C-reactive Protein (CRP) has been established as a prognostic biomarker in various malignancies, with elevated serum levels correlating with poorer outcomes. However, the significance of tissue-based CRP expression specifically in chromophobe renal cell carcinoma (chRCC), remains inadequately characterized. This study investigates the potential prognostic relevance of intratumoral CRP expression from a substantial cohort of chRCC patients. We conducted a retrospective analysis of patients who underwent surgical intervention for chRCC. Comprehensive clinical data was collected, and immunohistochemical evaluation of tumor specimens was performed to assess intratumoral CRP expression patterns. The study included 81 chRCC patients, with intratumoral CRP expression identified in 35 cases (43.2%). Statistical analysis revealed no significant correlation between CRP expression status and clinical parameters. While 5-year overall survival (OS) analysis showed no statistically significant difference between CRP-positive versus CRP-negative tumors (86.4% versus 100.0%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.106), overall follow-up demonstrated a significantly higher mortality rate in patients with CRP-positive tumors compared to those with CRP-negative tumors (22.9% vs. 2.2%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.013). Our findings suggest that intratumoral CRP expression in chRCC is not clearly associated with parameters of aggressiveness or survival. Further studies should assess the possible correlation between CRP tissue expression and blood levels. However, these findings should be interpreted with caution given the limited sample size, low event rate, and high loss to follow-up, and are best considered hypothesis-generating.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-60322-2","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:06:04Z","timestamp":1784045164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the clinical significance of tumor-expressed C-reactive protein in chromophobe renal cell carcinoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8546-0548","authenticated-orcid":false,"given":"Marie","family":"Mikuteit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Autenrieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilko","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Erlmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"60322_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/his.14700","author":"J Lobo","year":"2022","unstructured":"Lobo, J. et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology https:\/\/doi.org\/10.1111\/his.14700 (2022).","journal-title":"Histopathology"},{"issue":"5","key":"60322_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clgc.2019.06.011","volume":"17","author":"J Casuscelli","year":"2019","unstructured":"Casuscelli, J. et al. Chromophobe renal cell carcinoma: Results from a large single-institution series. Clin. Genitourin. Cancer 17(5), 373\u20139.e4. https:\/\/doi.org\/10.1016\/j.clgc.2019.06.011 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"60322_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch, H. et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-Part A: Renal, penile, and testicular tumours. Eur. Urol. 82(5), 458\u2013468. https:\/\/doi.org\/10.1016\/j.eururo.2022.06.016 (2022).","journal-title":"Eur. Urol."},{"issue":"3","key":"60322_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/CCO.0000000000001138","volume":"37","author":"V Wong","year":"2025","unstructured":"Wong, V., Goodstein, T., Montenegro, G. B., Srinivasan, R. & Singer, E. A. Biomarkers in advanced renal cell carcinoma: Current practice and future directions. Curr. Opin. Oncol. 37(3), 274\u2013282. https:\/\/doi.org\/10.1097\/CCO.0000000000001138 (2025).","journal-title":"Curr. Opin. Oncol."},{"issue":"47","key":"60322_CR5","doi-asserted-by":"publisher","first-page":"48487","DOI":"10.1074\/jbc.R400025200","volume":"279","author":"S Black","year":"2004","unstructured":"Black, S., Kushner, I. & Samols, D. C-reactive protein. J. Biol. Chem. 279(47), 48487\u201348490. https:\/\/doi.org\/10.1074\/jbc.R400025200 (2004).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"60322_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/B:THRO.0000037664.77460.d8","volume":"17","author":"SP Mazer","year":"2004","unstructured":"Mazer, S. P. & Rabbani, L. E. Evidence for C-reactive protein\u2019s role in (CRP) vascular disease: Atherothrombosis, immuno-regulation and CRP. J. Thromb. Thromb. 17(2), 95\u2013105. https:\/\/doi.org\/10.1023\/B:THRO.0000037664.77460.d8 (2004).","journal-title":"J. Thromb. Thromb."},{"issue":"Suppl 6","key":"60322_CR7","doi-asserted-by":"publisher","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","volume":"51","author":"J Kay","year":"2012","unstructured":"Kay, J. & Upchurch, K. S. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51(Suppl 6), vi5-9. https:\/\/doi.org\/10.1093\/rheumatology\/kes279 (2012).","journal-title":"Rheumatology"},{"key":"60322_CR8","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston, N. R. & Ashworth, J. J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol. 9, 754. https:\/\/doi.org\/10.3389\/fimmu.2018.00754 (2018).","journal-title":"Front. Immunol."},{"issue":"11","key":"60322_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1515\/hsz-2015-0149","volume":"396","author":"Y Wu","year":"2015","unstructured":"Wu, Y., Potempa, L. A., El Kebir, D. & Filep, J. G. C-reactive protein and inflammation: Conformational changes affect function. Biol. Chem. 396(11), 1181\u20131197. https:\/\/doi.org\/10.1515\/hsz-2015-0149 (2015).","journal-title":"Biol. Chem."},{"issue":"5","key":"60322_CR10","first-page":"471","volume":"32","author":"CS Wang","year":"2009","unstructured":"Wang, C. S. & Sun, C. F. C-reactive protein and malignancy: Clinico-pathological association and therapeutic implication. Chang. Gung. Med. J. 32(5), 471\u2013482 (2009).","journal-title":"Chang. Gung. Med. J."},{"key":"60322_CR11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/OTT.S235027","volume":"13","author":"H Wang","year":"2020","unstructured":"Wang, H., Wang, M. S., Zhou, Y. H., Shi, J. P. & Wang, W. J. Prognostic values of LDH and CRP in cervical cancer. Onco Targets Ther. 13, 1255\u20131263. https:\/\/doi.org\/10.2147\/OTT.S235027 (2020).","journal-title":"Onco Targets Ther."},{"key":"60322_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1471-2407-13-223","volume":"13","author":"S Steffens","year":"2013","unstructured":"Steffens, S. et al. High CRP values predict poor survival in patients with penile cancer. BMC Cancer 13, 223. https:\/\/doi.org\/10.1186\/1471-2407-13-223 (2013).","journal-title":"BMC Cancer"},{"issue":"19-20","key":"60322_CR13","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.cca.2012.05.009","volume":"413","author":"M Groblewska","year":"2012","unstructured":"Groblewska, M., Mroczko, B., Sosnowska, D. & Szmitkowski, M. Interleukin 6 and C-reactive protein in esophageal cancer. Clin. Chim. Acta 413(19\u201320), 1583\u20131590. https:\/\/doi.org\/10.1016\/j.cca.2012.05.009 (2012).","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"60322_CR14","doi-asserted-by":"publisher","first-page":"e1151","DOI":"10.1016\/j.clgc.2018.07.027","volume":"16","author":"T Nakayama","year":"2018","unstructured":"Nakayama, T. et al. Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin. Genitourin. Cancer 16(6), e1151\u2013e1158. https:\/\/doi.org\/10.1016\/j.clgc.2018.07.027 (2018).","journal-title":"Clin. Genitourin. Cancer"},{"key":"60322_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/1471-2407-12-399","volume":"12","author":"S Steffens","year":"2012","unstructured":"Steffens, S. et al. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 12, 399. https:\/\/doi.org\/10.1186\/1471-2407-12-399 (2012).","journal-title":"BMC Cancer"},{"issue":"10","key":"60322_CR16","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00345-023-04545-2","volume":"41","author":"M Guer","year":"2023","unstructured":"Guer, M., Janitzky, A. & Schostak, M. On-treatment risk model for predicting treatment response in advanced renal cell carcinoma. World J. Urol. 41(10), 2735\u20132742. https:\/\/doi.org\/10.1007\/s00345-023-04545-2 (2023).","journal-title":"World J. Urol."},{"issue":"3","key":"60322_CR17","doi-asserted-by":"publisher","first-page":"102098","DOI":"10.1016\/j.clgc.2024.102098","volume":"22","author":"C Saitta","year":"2024","unstructured":"Saitta, C. et al. Association of elevated C-reactive protein with worsened outcomes in different histologies of renal cortical tumors: Analysis of the INMARC registry. Clin. Genitourin. Cancer 22(3), 102098. https:\/\/doi.org\/10.1016\/j.clgc.2024.102098 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"60322_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00418-015-1324-4","volume":"144","author":"F Erlmeier","year":"2015","unstructured":"Erlmeier, F. et al. Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes. Histochem. Cell Biol. 144(2), 147\u2013156. https:\/\/doi.org\/10.1007\/s00418-015-1324-4 (2015).","journal-title":"Histochem. Cell Biol."},{"issue":"Suppl 4","key":"60322_CR19","doi-asserted-by":"publisher","first-page":"S584","DOI":"10.1245\/s10434-014-3690-x","volume":"21","author":"Y Kurokawa","year":"2014","unstructured":"Kurokawa, Y. et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann. Surg. Oncol. 21(Suppl 4), S584\u2013S590. https:\/\/doi.org\/10.1245\/s10434-014-3690-x (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"60322_CR20","doi-asserted-by":"publisher","first-page":"1170443","DOI":"10.3389\/fimmu.2023.1170443","volume":"14","author":"AH K\u00f8stner","year":"2023","unstructured":"K\u00f8stner, A. H. et al. Fueling the flames of colon cancer\u2014Does CRP play a direct pro-inflammatory role?. Front. Immunol. 14, 1170443. https:\/\/doi.org\/10.3389\/fimmu.2023.1170443 (2023).","journal-title":"Front. Immunol."},{"issue":"23","key":"60322_CR21","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO-25-00234","volume":"43","author":"C Labaki","year":"2025","unstructured":"Labaki, C. et al. Tumor-intrinsic and microenvironmental determinants of impaired antitumor immunity in chromophobe renal cell carcinoma. J. Clin. Oncol. 43(23), 2639\u20132654. https:\/\/doi.org\/10.1200\/JCO-25-00234 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"60322_CR22","doi-asserted-by":"publisher","first-page":"e70013","DOI":"10.1002\/cti2.70013","volume":"13","author":"C Pan","year":"2024","unstructured":"Pan, C. et al. The contribution of the CRP\/CD64 axis to renal cancer progression by inducing protumor activation of tumor-associated macrophages. Clin. Transl. Immunol. 13(11), e70013. https:\/\/doi.org\/10.1002\/cti2.70013 (2024).","journal-title":"Clin. Transl. Immunol."},{"key":"60322_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59091609","author":"D Yoo","year":"2023","unstructured":"Yoo, D., Min, K. W., Pyo, J. S. & Kim, N. Y. Diagnostic roles of immunohistochemical markers CK20, CD44, AMACR, and p53 in urothelial carcinoma in situ. Medicina https:\/\/doi.org\/10.3390\/medicina59091609 (2023).","journal-title":"Medicina"},{"key":"60322_CR24","doi-asserted-by":"publisher","first-page":"721989","DOI":"10.3389\/fimmu.2021.721989","volume":"12","author":"D O\u2019Brian","year":"2021","unstructured":"O\u2019Brian, D., Prunty, M., Hill, A. & Shoag, J. The role of C-reactive protein in kidney, bladder, and prostate cancers. Front. Immunol. 12, 721989. https:\/\/doi.org\/10.3389\/fimmu.2021.721989 (2021).","journal-title":"Front. Immunol."},{"issue":"5","key":"60322_CR25","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1523-1755.2005.00666.x","volume":"68","author":"WJ Jabs","year":"2005","unstructured":"Jabs, W. J. et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 68(5), 2103\u20132110. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00666.x (2005).","journal-title":"Kidney Int."},{"key":"60322_CR26","doi-asserted-by":"publisher","first-page":"595835","DOI":"10.3389\/fimmu.2020.595835","volume":"11","author":"PC Hart","year":"2020","unstructured":"Hart, P. C., Rajab, I. M., Alebraheem, M. & Potempa, L. A. C-reactive protein and cancer-diagnostic and therapeutic insights. Front. Immunol. 11, 595835. https:\/\/doi.org\/10.3389\/fimmu.2020.595835 (2020).","journal-title":"Front. Immunol."},{"issue":"3","key":"60322_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00595-012-0294-6","volume":"43","author":"S Motoyama","year":"2013","unstructured":"Motoyama, S. et al. A CRP genetic polymorphism associated with the tumoral expression of CRP in esophageal cancer. Surg. Today 43(3), 339\u2013340. https:\/\/doi.org\/10.1007\/s00595-012-0294-6 (2013).","journal-title":"Surg. Today"},{"issue":"11","key":"60322_CR28","doi-asserted-by":"publisher","first-page":"662.e1","DOI":"10.1016\/j.urolonc.2017.07.008","volume":"35","author":"J Teishima","year":"2017","unstructured":"Teishima, J. et al. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Urol. Oncol. 35(11), 662.e1. https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.008 (2017).","journal-title":"Urol. Oncol."},{"issue":"10","key":"60322_CR29","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1002\/cti2.1471","volume":"12","author":"B Hoeh","year":"2023","unstructured":"Hoeh, B. et al. Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: An updated multicentre real-world experience applying different CRP kinetics definitions. Clin. Transl. Immunol. 12(10), e1471. https:\/\/doi.org\/10.1002\/cti2.1471 (2023).","journal-title":"Clin. Transl. Immunol."},{"key":"60322_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225659","author":"Y Yano","year":"2022","unstructured":"Yano, Y. et al. Serum C-reactive protein level predicts overall survival for clear cell and non-clear cell renal cell carcinoma treated with ipilimumab plus nivolumab. Cancers https:\/\/doi.org\/10.3390\/cancers14225659 (2022).","journal-title":"Cancers"},{"issue":"3","key":"60322_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/bju.15200","volume":"127","author":"BH Cotta","year":"2021","unstructured":"Cotta, B. H. et al. Elevated preoperative C-reactive protein is associated with renal functional decline and non-cancer mortality in surgically treated renal cell carcinoma: Analysis from the INternational Marker Consortium for Renal Cancer (INMARC). BJU Int. 127(3), 311\u2013317. https:\/\/doi.org\/10.1111\/bju.15200 (2021).","journal-title":"BJU Int."},{"key":"60322_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071956","author":"F Esposito","year":"2022","unstructured":"Esposito, F., Matthes, H. & Schad, F. Seven COVID-19 patients treated with C-reactive protein (CRP) apheresis. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11071956 (2022).","journal-title":"J. Clin. Med."},{"key":"60322_CR33","doi-asserted-by":"publisher","first-page":"591714","DOI":"10.3389\/fcvm.2021.591714","volume":"8","author":"W Ries","year":"2021","unstructured":"Ries, W. et al. C-Reactive protein apheresis as anti-inflammatory therapy in acute myocardial infarction: Results of the CAMI-1 study. Front. Cardiovasc. Med. 8, 591714. https:\/\/doi.org\/10.3389\/fcvm.2021.591714 (2021).","journal-title":"Front. Cardiovasc. Med."},{"issue":"3","key":"60322_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MOU.0000000000000603","volume":"29","author":"G Lughezzani","year":"2019","unstructured":"Lughezzani, G., Paciotti, M., Fasulo, V., Casale, P. & Saita, A. Gender-specific risk factors for renal cell carcinoma: A systematic review. Curr. Opin. Urol. 29(3), 272\u2013278. https:\/\/doi.org\/10.1097\/MOU.0000000000000603 (2019).","journal-title":"Curr. Opin. Urol."},{"issue":"1","key":"60322_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23(1), 313\u201326.e5. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.075 (2018).","journal-title":"Cell Rep."},{"issue":"4","key":"60322_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.17305\/bjbms.2021.6935","volume":"22","author":"J Rogala","year":"2022","unstructured":"Rogala, J. et al. Small cell variant of chromophobe renal cell carcinoma: Clinicopathologic and molecular-genetic analysis of 10 cases. Bosn. J. Basic Med. Sci. 22(4), 531\u2013539. https:\/\/doi.org\/10.17305\/bjbms.2021.6935 (2022).","journal-title":"Bosn. J. Basic Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60322-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60322-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:22:01Z","timestamp":1784046121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60322-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60322"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60322-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures have been approved by the Ethics Committee of the Technical University of Munich (384\/13) and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Details that disclose the identity of the subjects under study were omitted. Clinical trial number: not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent of all participants was assessed prior to intervention.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22077"}}